Time to Progression every 8 weeks up to a maximum of 36 months [clinicaltrials_resource:530fcf38749662606202d7cc0ab8c1eb]
The number of months measured from the day of randomization to the first tumor progression according to World Health Organization (WHO) criteria evaluation of cancer response, or death from any cause.
WHO Criteria for Progressive Disease: ≥ 25% increase in the size of at least one bidimensionally or unidimensionally measurable lesion.
clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]
Time to Progression every 8 weeks up to a maximum of 36 months [clinicaltrials_resource:530fcf38749662606202d7cc0ab8c1eb]
The number of months measured from the day of randomization to the first tumor progression according to World Health Organization (WHO) criteria evaluation of cancer response, or death from any cause.
WHO Criteria for Progressive Disease: ≥ 25% increase in the size of at least one bidimensionally or unidimensionally measurable lesion.
Bio2RDF identifier
530fcf38749662606202d7cc0ab8c1eb
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:530fcf38749662606202d7cc0ab8c1eb
measure [clinicaltrials_vocabulary:measure]
Time to Progression
time frame [clinicaltrials_vocabulary:time-frame]
every 8 weeks up to a maximum of 36 months
description
The number of months measured ...... mensionally measurable lesion.
identifier
clinicaltrials_resource:530fcf38749662606202d7cc0ab8c1eb
title
Time to Progression every 8 weeks up to a maximum of 36 months
@en
type
label
Time to Progression every 8 we ...... fcf38749662606202d7cc0ab8c1eb]
@en